Home Medizin Optimierung der Chemotherapie für ältere Erwachsene mit fortgeschrittenem Krebs

Optimierung der Chemotherapie für ältere Erwachsene mit fortgeschrittenem Krebs

von NFI Redaktion


Standard chemotherapies, which are mostly based on tests on relatively young and healthy patients, can cause more harm to older adults with cancer who often struggle with other health issues. Recent research published in JAMA Network Open yesterday shows that reducing the dose and adjusting the schedule of chemotherapy for older adults with advanced cancer could improve patients‘ lives without jeopardizing their treatment goals.

The study, led by researchers from the Wilmot Cancer Institute at the University of Rochester Medical Center, focused on how well older individuals tolerate chemotherapy. More than 30% of the patients benefited from changes to the treatment schedule, helping them to avoid toxic side effects and retain the ability to perform everyday tasks such as bathing, dressing, eating, and walking on their own.

Wilmot researchers Mostafa R. Mohamed, MD, PhD, and Supriya G. Mohile, MD, MS, led the study, which analyzed data from over 600 study participants over the age of 70 who were part of the national clinical trial known as GAP70+.

Close to half of all GAP70+ participants received a modified treatment schedule, defined as any treatments deviating from the National Comprehensive Cancer Network guidelines or published clinical trials. Lower doses and modified chemotherapy plans were the most commonly observed modifications in the study.

Compared to patients receiving standard treatment schedules, patients on modified treatments had a 15% lower risk of serious physician-assessed toxic effects and a 20% lower risk of patient-reported functional decline. Patients on modified treatment schedules were also 32% less likely to achieve a worse combined undesirable outcome, suggesting that treatment modification did not compromise effectiveness.

This study is one of the few that exclusively focuses on older adults receiving chemotherapy for advanced cancer. The authors believe that this information can help healthcare providers choose the best care plans for older patients with advanced cancer.

Source:

University of Rochester Medical Center

Journal reference:

Mohamed, MR, et al. (2024). Modification of primary treatment and tolerability of treatment in older chemotherapy recipients with advanced cancer. JAMA Network Open. doi.org/10.1001/jamanetworkopen.2023.56106.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.